Progesterone Receptor (PR) [16]

Product Description

Progesterone Receptor antibody (PR) content of breast cancer tissue is an important parameter in the prediction of prognosis and response to endocrine therapy. PR [16] is directed against the human progesterone receptor molecule. A prokaryotic recombinant protein, corresponding to the N-terminal region of the A-form of human progesterone receptor, was used as the immunogen. Antibody characterization studies demonstrated that PR [16] reacts with both A- and B- forms of human progesterone receptor in Western Blotting procedures.

Specifications

1. Qiu J, et al. Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones. Am J Clin Pathol. 2010 Nov; 134(5):813-9.
2. Arihito K, et al. Comparison of evaluations for hormone receptors in breast carcinomas using two manual and three automated immunohistochemical assays. Am J Clin Pathol. 2007 Mar; 127(3):356-65.
3. Press M, et al. Comparison of different antibodies for detection of progesterone receptor in breast cancer steroids. Steroids. 2002 Aug; 67(9):799-813.
4. Mote P, et al. Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol. 2001 Aug; 54(8):624-30.
5. Bevitt D, et al. New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry. J Pathol. 1997 Oct; 183(3):228-32.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
7. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.